MedQuist Inc.
1000 Bishops Gate Boulevard
Suite 300
Mount Laurel,
NJ 08054-4632
United States - Map
Phone: 856-206-4000
Fax: 856-206-4020
Web Site: http://www.medquist.com
| MedQuist Inc. provides medical transcription technology and services in the United States. It also offers digital dictation, speech recognition, and electronic signature technologies. The company provides medical transcription services utilizing the DocQment Enterprise Platform, a Web-based dictation and medical transcription management system, which integrates dictation capture, workflow management, speech recognition, medical transcription, and document distribution. Its maintenance services include onsite maintenance and remote break-fix services, as well as application, hardware, and software technical support for its products. In addition, the company offers SpeechQ for Radiology, a front-end speech recognition software application that allows radiologists to dictate, edit, and sign their reports in a single session or send them to an editor following dictation; and DocQvoice, a Web-based enterprise digital voice capture and transport solution. It serves health systems, hospitals, and large group medical practices. The company was founded in 1984 and is headquartered in Mount Laurel, New Jersey. MedQuist Inc. operates as a subsidiary of CBaySystems Holdings Limited. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Peter Masanotti , 54
Chief Exec. Officer and Pres |
$
125.00K | N/A | Mr. Michael F. Clark , 46
Chief Operating Officer |
$
501.00K | N/A | Mr. James Brennan , 62
Principal Accounting Officer, VP, Treasurer and Controller |
$
286.00K | N/A | Mr. Mark E. Ivie , 50
Chief Technology Officer |
$
515.00K | N/A | Mr. Mark R. Sullivan , 38
Chief Compliance Officer, Sec. and Gen. Counsel |
$
498.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.45% Nasdaq 
0.20%
Profile
